Is 2005.HK overvalued or undervalued?

2005.HK currently has a P/E ratio of 15.31. Relative to the sector average of 15.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy SSY Group Limited stock?

SSY Group Limited trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 2005.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 2005.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 2005.HK to protect their purchasing power. Because 2005.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 2005.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 2005.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 2005.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks2005.HK

SSY Group Limited

HK$2.67-HK$0.11-3.96%

HKSE / HKD

Market cap

HK$7.7B

P/E

15.3

EPS (TTM)

HK$0.02

Dividend yield

3.00%

Beta

0.51

1Y return

-10.40%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$687M2021

$824M2022

$827M2023

$743M2024

$535M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.52Low
Current ratio1.87
Cash ratio0.69
Net margin11.6%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

2005.HK15.3
Healthcare sector median15.8
S&P 50022.0

Trades about 3% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.59
Price to book0.99
EPS (TTM)HK$0.02
Payout ratio4,603%
FCF yield3.61%

Range & risk

HK$2.01HK$3.18

Trading in the middle of its 52-week band

Beta0.51

Profile

What SSY Group Limited actually does

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.

CEO

Ji Guang Qu

Employees

5,400

Headquarters

Hong Kong

Founded

2005-12-20

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 2005.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

2005.HK has a beta of 0.51, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

SSY Group Limited